Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Ovid Therapeutics Inc. OVID

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.3M
▲ 1181.3% YoY
$-17.4M
$-38.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 7.3M
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.3 · Net income -17.4
100M200M-30M-60M
20152018202120242025
Compound annual growth
+69.0%
−10.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −10.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−240 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -585.2% · Net -240.1%
-5000%-10000%-15000%
201520202025
ROE
FY2025 · ROE -17.5%
50%100%-50%-100%
201520202025
Three returns, three denominators.

Each USD of equity lost 18 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -38.3
50M100M-20M-40M
201520202025

Total assetsUSD 150.9M
EquityUSD 130.7M
CashUSD 13.2M
Current ratio8.97×

Equity funds 87% of total assets.

The 11-year record

11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
OVID, 11-year financial record
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.20.0◌◌◌◌◌
Operating income $B−0.0−0.1−0.1−0.10.1−0.1−0.1−0.1−0.1−0.0−0.0
EBITDA $B−0.0−0.1−0.1−0.10.1−0.1−0.1−0.1−0.1−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.0◌◌
Net income $B−0.0−0.0−0.1−0.10.1−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.0−0.1−0.0−0.10.1−0.1−0.1−0.0−0.0−0.0−0.0
EPS, diluted $◌◌−0.74−0.771.76−1.39◌−2.11−3.35−2.28−1.36
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————
ROE %−17.5−33.9−47.6−34.7110.0−142.6−111.1−85.0−97.7−38.2−19.3
Shares out B0.130.070.070.070.070.070.050.020.020.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 39 reconciliationsAUDITED

Reconciled in 11 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image